Biological properties of the antagonist SRI 63–441 in the PAF and endotoxin models of hypotension in the rat and dog
- 1 April 1987
- journal article
- research article
- Published by Elsevier in Immunopharmacology
- Vol. 13 (2), 125-132
- https://doi.org/10.1016/0162-3109(87)90049-x
Abstract
No abstract availableThis publication has 43 references indexed in Scilit:
- Platelet activating factor and inflammation in atherogenesis: Targets for drug developmentDrug Development Research, 1986
- In vivo inhibition of plasma protein leakage andSalmonella enteritidis—induced mortality in the rat by a specific paf-acether antagonist: BN 52021Inflammation Research, 1986
- Inhibition of Rhesus Monkey Airway and Cutaneous Responses to Platelet-Activating Factor (PAF) (AGEPC) with the Anti-PAF Agent SRI 63-072International Archives of Allergy and Immunology, 1986
- Mechanism(s) of the hypotensive effect of synthetic 1-O-octadecyl-2-O-acetyl-glycero-3-phosphorylcholineEuropean Journal of Pharmacology, 1984
- Effect of 1-alkyl-2-acetyl--glycero-3-phosphorylcholine inhibitor on the reduction of one-kidney, one clip hypertension after unclipping in the ratLife Sciences, 1984
- CV-3988 - A specific antagonist of platelet activating factor (PAF)Life Sciences, 1983
- Alkyl ether analogs of phosphatidylcholine are orally active in hypertensive rabbits.Hypertension, 1981
- Antihypertensive activity of an alkyl ether analog of phosphatidylcholineBiochemical and Biophysical Research Communications, 1979
- The role of platelet-activating factor in platelet aggregationNature, 1979
- Platelet‐activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytesEuropean Journal of Immunology, 1979